$21.01
-0.28-1.32%
At close: -
$21.01
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Travere Therapeutics Stock Guidance | NASDAQ:TVTX | Benzinga
Travere Therapeutics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 01/09/2023 | TVTX | Travere Therapeutics | FY | 2022 | — | — | — | $212.00M | $212.00M | $212.08M | Get Alert |
| 01/10/2022 | TVTX | Travere Therapeutics | FY | 2021 | — | — | — | $227.00M | $227.00M | $227.25M | Get Alert |
| 01/11/2021 | TVTX | Travere Therapeutics | Q4 | 2020 | — | — | — | $51.00M | $51.00M | $51.33M | Get Alert |
| 01/11/2021 | TVTX | Travere Therapeutics | FY | 2020 | — | — | — | $199.00M | $199.00M | $198.61M | Get Alert |
FAQ
What is the most recent guidance for Travere Therapeutics (TVTX)?
There have been no specific sales or earnings guidance reported for Travere Therapeutics in recent months.
Browse guidance and forecast on all stocks.